ReviewNPJ breast cancer2023
Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2- breast cancer.
Review in NPJ breast cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The impact of menopausal status on the efficacy of adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: a systematic review and meta-analysis of phase III clinical trials.Breast cancer research and treatment · 2026Pooled it
- An international framework for clinical translation of molecular classifiers in osteosarcoma.NPJ precision oncology · 2026Article
- Innovations in biomarker stratification for precision oncology.Clinical and experimental medicine · 2026Review
- Treatment Experience of Early-Stage Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer in a Real-World Setting: European Patients' Perspectives.Breast care (Basel, Switzerland) · 2026Article
- Financial De-Escalation in T1 Breast Cancers With the Low Magee Equation: An Experience From A Single Institution Without Genomic Testing.European journal of breast health · 2025Article
- Feature learning augmented with sampling and heuristics (FLASH) improves model performance and biomarker identification.NPJ systems biology and applications · 2025Article
- Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor-Positive, Node-Positive Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Article
- Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence.Military Medical Research · 2025Review
- The Role of Molecular Profiling in De-Escalation of Toxic Therapy in Breast Cancer.International journal of molecular sciences · 2025Review
- Clinician's guide: expert insights on the use of CDK4/6 inhibitors in patients with early breast cancer.Therapeutic advances in medical oncology · 2025Review
- Article
- Navigating precision: the crucial role of next-generation sequencing recurrence risk assessment in tailoring adjuvant therapy for hormone receptor-positive, human epidermal growth factor Receptor2-negative early breast cancer.Cancer biology & therapy · 2024Review
- Potential Drug Synergy Through the ERBB2 Pathway in HER2+ Breast Tumors.International journal of molecular sciences · 2024Article
- Clinical evaluation of deep learning-based risk profiling in breast cancer histopathology and comparison to an established multigene assay.Breast cancer research and treatment · 2024Article
- The Evolving Role of Genomic Testing in Early Breast Cancer: Implications for Diagnosis, Prognosis, and Therapy.International journal of molecular sciences · 2024Review
- Advances in Early Breast Cancer Risk Profiling: From Histopathology to Molecular Technologies.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Stratification of recurrence risk is a cornerstone of early breast cancer diagnosis that informs a patient's optimal treatment pathway. Several tools exist that combine clinicopathological and molecular information, including multigene assays, which can estimate risk of recurrence and quantify the potential benefit of different adjuvant treatment modalities. While the tools endorsed by treatment guidelines are supported by level I and II evidence and provide similar prognostic accuracy at the population level, they can yield discordant risk prediction at the individual patient level. This review examines the evidence for these tools in clinical practice and offers a perspective of potential future risk stratification strategies. Experience from clinical trials with cyclin D kinase 4/6 (CDK4/6) inhibitors in the setting of hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) early breast cancer is provided as an illustrative example of risk stratification.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.